Kenya Depression Therapeutics Market Analysis

Kenya Depression Therapeutics Market Analysis


$ 3999

Kenya's depression therapeutics market is expected to grow from $7 Mn in 2022 to $12 Mn in 2030 with a CAGR of 6.3% for the forecasted year 2022-30. The rising incidence of depression and the increasing disposable incomes of the citizens of Kenya are the major market drivers. The Kenya depression therapeutics market is segmented by drug type, therapies, indication, and end users. Jaskam & Company, Wessex Pharmaceuticals, and Bristol-Myers Squibb are the major players in the Kenya depression therapeutics market.

ID: IN10KEPH034 CATEGORY: Pharmaceuticals GEOGRAPHY: Kenya AUTHOR: Dr. Parul Choudhary

Buy Now

Kenya Depression Therapeutics Market Executive Analysis

Kenya's depression therapeutics market is expected to grow from $7 Mn in 2022 to $12 Mn in 2030 with a CAGR of 6.3% for the forecasted year 2022-30. The Kenyan government has budgeted $1.11 Bn for healthcare services in the fiscal year 2022-23. One of President Uhuru Kenyatta's four major priority items is health care. $0.47 Bn of the $1.11 Bn for health will be spent on initiatives and programs aimed at achieving universal coverage. $53 Mn has been set aside for the purchase of COVID-19 vaccines and associated expenses, with $31 Mn set aside for free maternity health care. $39 Mn will be spent on Managed Equipment Services, while $14 Mn will be used to provide medical coverage for the elderly and seriously disabled members of society.

According to recent WHO estimates, over 300 Mn individuals worldwide are depressed. Kenya, like the rest of the world, has approximately 1.9 Mn depression instances. After South Africa (2.4 Mn cases), the Democratic Republic of the Congo (2.9 Mn cases), Ethiopia (4.5 Mn cases), and Nigeria, it is listed fifth among African countries with the highest number of depression cases. (7.1 Mn cases).

Paroxetine tablets, suspension (liquid), and extended-release (long-acting) tablets are used to treat depression, panic disorder, and social anxiety disorder. Paroxetine tablets and suspension are also used to treat obsessive-compulsive disorder, generalized anxiety disorder, and posttraumatic stress disorder (PTSD). Paxil (paroxetine) was initially authorized as a much-needed and welcomed addition to the antidepressant/antianxiety inventory. Aside from being a serotonin reuptake inhibitor, it also had mild to moderate noradrenergic effects by inhibiting norepinephrine reuptake (NRI or NARI) and could be activating, which often assisted depressed patients with lethargy. Antidepressants act on the serotonin, norepinephrine, and/or dopamine chemical receptors in the brain. Tricyclic Antidepressants (TCAs) inhibit norepinephrine reuptake pumps, as well as serotonin reuptake, pumps to different degrees. Their impacts on acetylcholine, histamine, and adrenergic receptors frequently result in undesirable side effects. (e.g., weight gain, sedation, constipation, dry mouth, orthostatic hypotension, reflex tachycardia). Secondary amine TCAs (e.g., nortriptyline [Pamelor], desipramine [Norpramin]) have fewer adverse effects than tertiary amines (e.g., imipramine [Tofranil], amitriptyline).

Kenya Depression Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers

Depression is becoming more prevalent.  In recent years, there has been an increase in understanding and acceptance of mental health topics in Kenya. Depression therapeutics are in high demand as more people seek treatment for mental health problems. Kenya has been investing in its healthcare infrastructure, which includes hospitals, clinics, and medical personnel. This outlay is anticipated to improve access to mental health services, leading to a rise in demand for depression treatment. As the economy matures, many Kenyans' disposable income increases. As a result, there is a higher demand for healthcare services such as mental health services and depression treatment, which is driving the Kenya depression therapeutics market expansion.

Market Restraints

Despite ongoing funds for healthcare infrastructure, Kenya continues to face resource limitations, such as a lack of qualified mental health workers and inadequate access to mental health services in some parts. This could limit the progress of the market for depression therapeutics. Depression therapeutics can be expensive, which may limit their availability to many Kenyans who cannot afford the treatment. This could be a major impediment to market development. In Kenya, healthcare insurance coverage is limited, and many policies do not cover mental health treatments. This may limit the Kenya depression therapeutics market growth because many people may not have the monetary means to pay for treatment out of pocket.

Competitive Landscape

Key Players

  • Regal Pharmaceuticals (KEN)
  • Mac's Pharmaceuticals (KEN)
  • Sunpar Pharmaceuticals (KEN)
  • Jaskam & Company (KEN)
  • Wessex Pharmaceuticals (KEN)
  • Bristol-Myers Squibb
  • Cipla
  • Eli Lily
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Zydus Lifesciences

Healthcare Policies and Regulatory Landscape

Prior to 2015, the National Hospital Insurance Fund (NHIF) only provided rebates for inpatient services to its users. This arrangement lacked breadth for some critical medical services needed by its members, namely surgical care and specialized laboratory investigations. This meant that members were still paying out of pocket to receive advanced therapy. The NHIF, Kenya's national health insurance plan, covers some mental health services such as consultations, counselling, and medication. However, coverage is limited and may not be enough to cover the cost of more intensive depression therapy, such as inpatient care. Kenya currently has no reimbursement policies in effect for mental health care. This can make it difficult for mental health providers to obtain payment for their services, potentially resulting in limited access to care.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Depression Therapeutics Segmentation

By Drug Type (Revenue, USD Billion):

  • Antidepressants
  • Anxiolytics
  • Anticonvulsants
  • Noradrenergic Agents
  • Atypical Antipsychotics

By Therapies (Revenue, USD Billion):

  • Electroconvulsive Therapy (ECT)
  • Cognitive Behaviour Therapy (CBT)
  • Psychotherapy
  • Deep Brain Stimulation
  • Transcranial Magnetic Stimulation (TMS)
  • Cranial electrotherapy stimulation (CES)

By Indication (Revenue, USD Billion):

  • Major Depressive Disorder (MDD)
  • Bipolar Disorder
  • Dysthymic Disorder
  • Postpartum Depression
  • Seasonal Affective Disorder (SAD)
  • Premenstrual Dysphoric Disorder (PMDD)
  • Others

By End Users (Revenue, USD Billion):

  • NGOs
  • Asylums
  • Hospitals
  • Mental Healthcare Centers

Insights10 will provide you with the reports within 10 key parameters which are:

  1. Market Overview
  2. Market Growth Drivers & Restraints
  3. Epidemiology of Disease Type
  4. Market Segmentation
  5. Market Share
  6. Competitive Landscape
  7. Key Company Profiles
  8. Healthcare Policies & Regulatory Framework
  9. Reimbursement Scenario
  10. Factors Driving Future Growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

 

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

 

 

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and  Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.

We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.

 

 

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)

  • Establishing market drivers and trends
  • Analyzing the regulatory landscape to understand future growth
  • Market Segment based analysis to obtain revenue/volume
  • ​Analyzing current needs and determining penetration to estimate the market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.

Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.

The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.

Jaskam & Company, Wessex Pharmaceuticals, and Bristol-Myers Squibb are the major players in the Kenya depression therapeutics market.

The Kenya depression therapeutics market is expected to grow from $7 Mn in 2022 to $12 Mn in 2030 with a CAGR of 6.3% for the forecasted year 2022-2030.

The Kenya depression therapeutics market is segmented by drug type, therapies, indication, and by end users.


This report addresses

  • Intelligent insights to take informed business decisions
  • Qualitative, acute and result oriented market analysis
  • Market size and forecasts from 2022 to 2030
  • Opportunities for expansion and in-depth market analysis
  • Segmentation and regional revenue forecasts
  • Analysis of the market share and competitive landscape
  • Strategic Recommendations to chart future course of action
  • Comprehensive Market Research Report in PDF and PPT formats

Need more?

  • Ask our analyst how this study was put together to learn more
  • Discuss additional requirements as part of the free customisation
  • Add more countries or regions to the scope 
  • Get answers to specific business questions 
  • Develop the business case to launch the product
  • Find out how this report may influence your business revenue
Last updated on: 14 December 2023
Updated by: Riya Doshi

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up